Northeast Clinical Research Center

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease4 trials
• Type 2 diabetes3 trials
• Polycystic kidney disease2 trials
• Coronary artery disease1 trial
• Heart failure1 trial
• Nephrotic syndrome1 trial
• Obesity1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 24 trials
• Phase 32 trials
• Phase 11 trial

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Calico Life Sciences LLC1 trial
• Eli Lilly and Company1 trial
• Inversago Pharma Inc.1 trial
• Novo Nordisk A/S1 trial
• Regeneron Pharmaceuticals1 trial
• and 2 more

Running trials

• Recruiting

  Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

  NCT07271186· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· Phase 2· Calico Life Sciences LLC· Source

  Contact: Stephanie Hanzl, RN

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Polycystic kidney disease1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

  NCT05514548· Phase 2· Inversago Pharma Inc.· Source

• Completed

  A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05521191· Phase 1· Regulus Therapeutics Inc.· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

  NCT01613118· Phase 2· Travere Therapeutics, Inc.· Source